Phase I/II clinical trial of adoptive cell transfer of sorted specific T cells for metastatic melanoma patients - Archive ouverte HAL Access content directly
Journal Articles Cancer Immunology, Immunotherapy Year : 2021

Phase I/II clinical trial of adoptive cell transfer of sorted specific T cells for metastatic melanoma patients

(1, 2, 3, 4, 5) , (6, 2, 3, 4) , (7, 4) , (7, 4, 3) , (5) , (7, 4, 3) , (8, 4) , (5) , (7, 4) , (7, 4) , (7, 4, 8)
1
2
3
4
5
6
7
8

Abstract

Adoptive cell transfer (ACT) of tumor-specific T lymphocytes represents a relevant therapeutic strategy to treat metastatic melanoma patients. Ideal T-cells should combine tumor specificity and reactivity with survival in vivo, while avoiding autoimmune side effects. Here we report results from a Phase I/II clinical trial (NCT02424916, performed between 2015 and 2018) in which 6 metastatic HLA-A2 melanoma patients received autologous antigen-specific T-cells produced from PBMC, after peptide stimulation in vitro, followed by sorting with HLA-peptide multimers and amplification. Each patient received a combination of Melan-A and MELOE-1 polyclonal specific T-cells, whose specificity and anti-tumor reactivity were checked prior to injection, with subcutaneous IL-2. Transferred T-cells were also characterized in terms of functional avidity, diversity and phenotype and their blood persistence was evaluated. An increase in specific T-cells was detected in the blood of all patients at day 1 and progressively disappeared from day 7 onwards. No serious adverse events occurred after this ACT. Clinically, five patients progressed and one patient experienced a partial response following therapy. Melan-A and MELOE-1 specific T-cells infused to this patient were diverse, of high avidity, with a high proportion of T lymphocytes coexpressing PD-1 and TIGIT but few other exhaustion markers. In conclusion, we demonstrated the feasibility and safety of ACT with multimer-sorted Melan-A and MELOE-1 specific T cells to metastatic melanoma patients. The clinical efficacy of such therapeutic strategy could be further enhanced by the selection of highly reactive T-cells, based on PD-1 and TIGIT co-expression, and a combination with ICI, such as anti-PD-1.
Fichier principal
Vignette du fichier
Dreno et al., 2021.pdf (1.58 Mo) Télécharger le fichier
Origin : Publication funded by an institution

Dates and versions

inserm-03260784 , version 1 (15-06-2021)

Identifiers

Cite

Brigitte Dréno, Amir Khammari, Agnès Fortun, Virginie Vignard, Soraya Saiagh, et al.. Phase I/II clinical trial of adoptive cell transfer of sorted specific T cells for metastatic melanoma patients. Cancer Immunology, Immunotherapy, 2021, Online ahead of print. ⟨10.1007/s00262-021-02961-0⟩. ⟨inserm-03260784⟩
47 View
53 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More